A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS with IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)

Protocol No
BMS-CA0561060
Staff Member
Ravi Narra
Phase
III
Summary

This project is being done to learn more about Luspatercept if administrated at the maximum approved starting dose to assess that a quicker benefit can be seen in your transfusion burden and hemoglobin level.
Objective
Study of Luspatercept in lower-risk myelodysplastic syndrome participants
Status
OPEN TO ACCRUAL
Categories
Cancer, Other Blood Related, Leukemia, Hematologic/Blood Related Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT06045689